News
Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...
19h
Pharmaceutical Technology on MSNEC approves BeOne’s Tevimbra for nasopharyngeal carcinomaBeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.
Libtayo works by attaching itself to a receptor called programmed cell death protein 1 (PD-1) on specific immune system cells called T cells.
A collaborative study from the University of Cologne has uncovered how a key mitochondrial protein, AIFM1 (Apoptosis-Inducing ...
4d
News Medical on MSNMCL-1 Discovery Unlocks New Cancer StrategiesLandmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why ...
Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...
The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...
A pioneering discovery at WEHI in 1988 of a protein that stopped programmed cell death sparked huge interest in the field, and has since led to a new drug to treat cancer.
Researchers at the University of Cologne have identified the key mitochondrial protein AIFM1 as a central coordinator of cellular energy production.
The authors noted that there are currently 3 immune-oncologic antibody treatments approved for locally advanced and metastatic cSCCs that target the programmed cell death protein 1/programmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results